Premium
Potential of fosfomycin in treating multidrug‐resistant infections in children
Author(s) -
Williams Phoebe CM
Publication year - 2020
Publication title -
journal of paediatrics and child health
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.631
H-Index - 76
eISSN - 1440-1754
pISSN - 1034-4810
DOI - 10.1111/jpc.14883
Subject(s) - fosfomycin , medicine , intensive care medicine , antimicrobial , dosing , antibiotics , antibiotic resistance , multiple drug resistance , neonatal sepsis , clinical trial , sepsis , pharmacology , microbiology and biotechnology , biology
In an era of increasing antimicrobial resistance, there are limited treatment options available to treat multidrug‐resistant organisms in paediatric patients. Fosfomycin is an antibiotic defined as ‘critically important’ by The World Health Organization due to its potential efficacy against multidrug‐resistant bacteria and is increasingly cited in the international literature as a promising antimicrobial for combating sepsis in an era of increasing antimicrobial resistance. With broad‐spectrum cover that includes both Gram‐positive and Gram‐negative organisms and both parenteral and oral formulations available, fosfomycin provides a promising treatment option for paediatric patients. This review summarises fosfomycin's spectrum of activity, published efficacy in paediatric patients, safety considerations and pharmacokinetic data, as well as identifying current clinical trials delineating pharmacokinetic parameters and safety parameters in neonatal sepsis which will provide further information regarding the use of fosfomycin in neonatal and paediatric infections. Limitations regarding the current standards for fosfomycin susceptibility definitions, variations in dosing regimens and the potential mechanisms for resistance are also discussed.